Skip to content

Corporate Research Collaborations

While most of our discovery and development programs are developed internally - making Allergan quite unique in the industry - we are continuously looking for partnerships and superior technology that complement our business model. Some of our current collaborations include:

  • An exclusive licensing agreement with Sanwa Kagaku Kenkyusho Co., Ltd. (Sanwa) to develop and commercialize POSURDEX® for the ophthalmic specialty market in Japan. POSURDEX® is a form of dexamethasone, which can be delivered in a bioerodable implant for macular edema and retinal vein occlusion.
  • A multi-year alliance with Sirna Therapeutics, Inc. to develop Sirna-027, a novel RNAi-based therapeutic currently in clinical trials for age-related macular degeneration and to discover and develop other novel RNAi-based therapeutics against select gene targets for ophthalmic diseases.
  • A license with Inspire Pharmaceuticals, Inc. to develop and commercialize Prolacria™ (diquafosol tetrasodium ophthalmic solution 2%), that Inspire is investigating for the treatment of dry eye.
  • A strategic research collaboration and license agreement with ExonHit Therapeutics to identify new molecular targets based on ExonHit Therapeutics' gene profiling DATAS™ technology and to work collaboratively on the development of unique compounds and commercial products based on these targets.
  • An exclusive worldwide alliance with ACADIA Pharmaceuticals for the discovery of alpha adrenergic drug candidates for treatments in ophthalmology and pain.
  • An exclusive licensing agreement with Kyorin Pharmaceutical Co., Ltd. to develop and commercialize ALPHAGAN® and ALPHAGAN® P for the ophthalmic specialty market in Japan.
  • An exclusive licensing agreement with Senju Pharmaceutical Co., Ltd. to develop and commercialize LUMIGAN® for the ophthalmic specialty market in Japan.
  • An arrangement with Stiefel Laboratories, Inc. where Stiefel will develop, manufacture, distribute and promote dermatological products containing Allergan’s innovative tazarotene compound.